FeedHome » AMRI, New River Announces Manufacturing Agreement
AMRI, New River Announces Manufacturing Agreement
Pharmalive.com
PharmaManufacturing.com
07/27/2006
Under the agreement, AMRI will manufacture the active pharmaceutical ingredient in New River's compound, NRP104, a new treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the U.S. Food and Drug Administration. AMRI participated with New River in the development of the chemical process to manufacture NRP104.
"AMRI is delighted to continue its relationship with New River Pharmaceuticals," said AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. "We are well positioned to manufacture this compound based on our long history of manufacturing, as well as our strength in chemical development. Our expertise and specialized capabilities in the area of active ingredient manufacturing provide a unique and value-added capability to AMRI customers."
Krish Krishnan, New River's Chief Financial Officer and Chief Operating Officer, commented, "We are confident that AMRI is a solid choice for manufacture. AMRI has the current capability of delivering a quality product in a timely manner, leading us to conclude that it is the best candidate for manufacturing NRP104 for an expected product launch in the first quarter of 2007."
Albany Molecular Research, Inc.
Albany Molecular Research, Inc. is a global drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs.
New River Pharmaceuticals Inc.
New River Pharmaceuticals Inc. is a specialty pharmaceutical company developing novel pharmaceuticals that are generational improvements of widely prescribed drugs in large and growing markets. For further information on New River, please visit the company's website at www.nrpharma.com.
.